Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

Table 1 Blood test schedule following treatment with I¹³¹ KAb201

Blood test	Time points
Haematology	Day of treatment and days 5, 7, 11, 14, 28, 42, 60 and 90 post treatment
Biochemistry	Day of treatment and days 5, 7, 11, 14, 28, 42, 60 and 90 post treatment
Pharmacokinetics and radioactivity levels	Days 1, 2, 5, 7, 11, 14, 28, 42, 60 and 90 post treatment
HASA/HACA	Days 14, 28, 42, 60 and 90 post treatment
Serum CEA/CA19-9	Days 28, 60 and 90 post treatment
CEA complexing assay	6 hours post dosimetry

HASA = Human antisheep antibody; HACA = Human anti-chimaeric antibody; CEA = Carcino-Embryonic antigen

ISSN: 1471-2407